On June 30, 2017, Stanley Yarbro sent a letter to the Board expressing his ongoing concern regarding the underperformance and mismanagement of Calmare Therapeutics Incorporated. In the letter, Stanley Yarbro noted that, despite languishing stock price, senior management’s compensation has done nothing but go up and that senior management’s compensation is in no way tied to shareholder return. The letter also noted that Stanley Yarbro’s concern with the Board’s recent invalid and wrongful removal of Stanley Yarbro as a member of the Board. Stanley Yarbro stated that the letter requested that the Board have a meeting with the Stanley Yarbro to address the above-referenced concerns.